4.7 Article

Multidimensional analysis and therapeutic development using patient iPSC-derived disease models of Wolfram syndrome

Journal

JCI INSIGHT
Volume 7, Issue 18, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.156549

Keywords

-

Funding

  1. NIH/National Institute of Diabetes and Digestive and Kidney Diseases [DK112921, DK020579, DK114233, DK127497]
  2. NIH/NCATS [TR002065, TR000448]
  3. JDRF [5-CDA-2017-391-A-N]
  4. Silberman Fund
  5. Ellie White Foundation
  6. Snow Foundation
  7. Unravel Wolfram Syndrome Fund
  8. Stowe Fund
  9. Feiock Fund
  10. Cachia Fund
  11. Gildenhorn Fund
  12. Eye Hope Foundation
  13. Ontario Wolfram League
  14. Associazione Gentian -Sindrome di Wolfram Italia
  15. Alianza de Familias Afectadas por el Sindrome Wolfram Spain
  16. Wolfram Syndrome UK
  17. Association Syndrome de Wolfram France
  18. Washington University Institute of Clinical and Translational Sciences grant from the NIH/NCATS [UL1TR002345]
  19. NIH/NCATS

Ask authors/readers for more resources

Wolfram syndrome is a rare genetic disorder characterized by diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration, largely caused by mutations in the WFS1 gene. Recent studies have shown that Wolfram syndrome is a spectrum disorder and a genotype-phenotype correlation analysis is needed for diagnosis and treatment development. This study focused on a common WFS1 gene variant in the Ashkenazi Jewish population, which was associated with milder forms of Wolfram syndrome. By using induced pluripotent stem cells, the researchers found that a combination treatment of chemical chaperones could mitigate the detrimental effects caused by the variant and increase insulin secretion. Thus, this study provides a valuable platform for further genotype-phenotype analysis and therapeutic development for Wolfram syndrome.
Wolfram syndrome is a rare genetic disorder largely caused by pathogenic variants in the WFS1 gene and manifested by diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration. Recent genetic and clinical findings have revealed Wolfram syndrome as a spectrum disorder. Therefore, a genotype-phenotype correlation analysis is needed for diagnosis and therapeutic development. Here, we focus on the WFS1 c.1672C>T, p.R558C variant, which is highly prevalent in the Ashkenazi Jewish population. Clinical investigation indicated that patients carrying the homozygous WFS1 c.1672C>T, p.R558C variant showed mild forms of Wolfram syndrome phenotypes. Expression of WFS1 p.R558C was more stable compared with the other known recessive pathogenic variants associated with Wolfram syndrome. Human induced pluripotent stem cell-derived (iPSC-derived) islets (SC-islets) homozygous for WFS1 c.1672C>T variant recapitulated genotype-related Wolfram syndrome phenotypes. Enhancing residual WFS1 function through a combination treatment of chemical chaperones mitigated detrimental effects caused by the WFS1 c.1672C>T, p.R558C variant and increased insulin secretion in SC-islets. Thus, the WFS1 c.1672C>T, p.R558C variant causes a mild form of Wolfram syndrome phenotypes, which can be remitted with a combination treatment of chemical chaperones. We demonstrate that our patient iPSC-derived disease model provides a valuable platform for further genotype-phenotype analysis and therapeutic development for Wolfram syndrome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available